Department of Pharmaceutics, Faculty of Pharmacy, The Islamia University of Bahawalpur, Bahawalpur, 63100, Punjab, Pakistan.
Eur J Pharmacol. 2021 Mar 5;894:173854. doi: 10.1016/j.ejphar.2021.173854. Epub 2021 Jan 8.
The current outbreak of novel COVID-19 challenges the development of an efficient treatment plan as soon as possible. Several promising treatment options stand out as potential therapy of COVID-19, including plasma-derived drugs, monoclonal antibodies, antivirals, antimalarial, cell therapy, and corticosteroids. Dexamethasone an approved corticosteroid medication, acting as an anti-inflammatory and immunosuppressant agent. In the current pandemic, dexamethasone is declared a "major development" in the fight against COVID-19. Steroidal dexamethasone was presented as the recent advancement that significantly reduces the mortality rate among severe COVID-19 cases. This review summarizes the preliminary opinion about the dexamethasone outbreak, therapeutic potential, risks, and strategies during the COVID-19 pandemic.
目前新型 COVID-19 的爆发对尽快制定有效的治疗方案提出了挑战。有几种有前途的治疗选择被突出为 COVID-19 的潜在治疗方法，包括血浆衍生药物、单克隆抗体、抗病毒药物、抗疟药物、细胞疗法和皮质类固醇。地塞米松是一种已批准的皮质类固醇药物，具有抗炎和免疫抑制作用。在当前的大流行中，地塞米松被宣布为对抗 COVID-19 的“重大进展”。甾体地塞米松被认为是最近的一项进展，它显著降低了重症 COVID-19 病例的死亡率。这篇综述总结了关于 COVID-19 大流行期间地塞米松爆发、治疗潜力、风险和策略的初步意见。
